Skip to product information
1 of 1

FDA ANDA 212299, DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), ZYDUS LIFESCIENCES, 09/10/2020

FDA ANDA 212299, DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL), ZYDUS LIFESCIENCES, 09/10/2020

Regular price $696.52 USD
Regular price Sale price $696.52 USD
Sale Sold out

Contents: Approval letter, executive summary, quality assessment data sheets

ANDA: 212299
Company: ZYDUS LIFESCIENCES
Drug Name: DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
Active Ingredients: DOXORUBICIN HYDROCHLORIDE (LIPOSOMAL)
Strength: 20MG/10ML (2MG/ML)
Dosage Form/Route: INJECTABLE, LIPOSOMAL;INJECTION
Action Date: 09/10/2020
Marketing Status: Prescription
Submission Classification: ORIG-1

230 Pages

View full details
FOIA Pro

This drug has a lot more FDA history than one product page can show

FOIA Pro gives you full-text search across 70,000+ FDA FOIA records, from 2020 through today, plus a monthly monitor tracking new requests as they close.
  • Full-text search across every FDA FOIA log since 2020
  • Warning letters, approval records, and correspondence in one place
  • Monthly FDA FOIA Monitor newsletter, included
  • Cancel anytime, monthly or annual billing
Get FOIA Pro
Live search · FOIA database
Searching related FDA records…
ClosedTypeSubjectOutcome